drugset
drugset / Trial / NCT04543695

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

NCT04543695 ↗

Phase 2 Unknown 255 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences Cancer Hospital of Guizhou Province · collabJilin Provincial Tumor Hospital · collabPeking Union Medical College Hospital · collabPeking University Cancer Hospital & Institute · collabXijing Hospital · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase II Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

Timeline

Start
2020-08-15
Primary completion
2022-07-12
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Capecitabine Small molecule 1650 mg/m2 Oral
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject fluorouracil Small molecule 400 mg/m2 Intravenous
Subject fluorouracil Small molecule 2400 mg/m2 Intravenous
Subject l-LV Unknown 400 mg/m2 Intravenous

Indications

rectal cancer